Erratum: Prostate cancer mortality in areas with high and low prostate cancer incidence (Journal of the National Cancer Institute (2014) 106:3 (dju007) DOI: 10.1093/jnci/dju007);Prostate cancer mortality in areas with high and low prostate cancer incidence

Journal of the National Cancer Institute

Volumn 106, Issue 3, 2014, Pages

  Stattin, Par ^a,b   Carlsson, Sigrid ^b,d   Holmstrom, Benny ^a   Vickers, Andrew ^c   Hugosson, Jonas ^d   Lilja, Hans ^c,e,f,g   Jonsson, Hakan ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b Urology Service   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^g LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CAUSE OF DEATH; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE METASTASIS; PROSTATECTOMY; SWEDEN; BLOOD; EARLY DIAGNOSIS; IMMUNOLOGY; INCIDENCE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; REGISTER;

AGED; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MORTALITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84898741231     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju193     Document Type: Erratum

References (35)

1. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981-990.
2. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-732.
3. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125-132.
4. Moyer VA, US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
5. Volk RJ, Wolf AM. Grading the new US Preventive Services Task Force prostate cancer screening recommendation. JAMA. 2011;306(24):2715-2716.
6. Carlsson S, Vickers AJ, Roobol M, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol. 2012;30(21):2581-2584.
7. McNaughton-Collins MF, Barry MJ. One man at a time - resolving the PSA controversy. N Engl J Med. 2011;365(21):1951-1953.
8. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878-1886.
9. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887-1892.
10. Bartsch G, Horninger W, Klocker H, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008;101(7):809-816.
11. van Leeuwen PJ, Connolly D, Gavin A, et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer. 2010;46(2):377-383.
12. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery E, Barry MJ. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. J Gen Intern Med. 2008;23(11):1809-1814.
13. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002;325(7367):740.
14. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46(17):3040-3052.
15. Jonsson H, Holmstrom B, Duffy SW, Stattin P. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden. Int J Cancer. 2011;129(8):1881-1888.
16. Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42(4):956-967.
17. National Prostate Cancer Registry. Annual report. http://npcr.se. Accessed October 17, 2013.
18. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659-667.
19. National Board of Health and Welfare. Cancer Incidence in Sweden 2010. Stockholm: National Board of Health and Welfare; 2010.
20. Jonsson H, Bordas P, Wallin H, Nystrom L, Lenner P. Service screening with mammography in Northern Sweden: effects on breast cancer mortality - an update. J Med Screen. 2007;14(2):87-93.
21. Swedish Organised Service Screening Evaluation. Reduction in breast cancer mortality from organized service screening with mammography: further confirmation with extended data. Cancer Epidemiol Biomarkers Prev. 2006;15(1):45-51.
22. Lenner P, Jonsson H. Excess mortality from breast cancer in relation to mammography screening in northern Sweden. J Med Screen. 1997;4(1):6-9.
23. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8(2):162-200.
24. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostatecancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
25. Davison AC. Statistical Models. Cambridge, UK: Cambridge University Press; 2003.
26. International Agency for Research on Cancer. GLOBOCAN. http://globocan. iarc.fr/factsheet.asp.
27. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27-33.
28. Godtman R, Holmberg E, Stranne J, Hugosson J. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol. 2011;45(4):226-232.
29. Fall K, Stromberg F, Rosell J, Andren O, Varenhorst E, South-East Region Prostate Cancer Group. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008;42(4):352-357.
30. Stattin P, Holmberg E, Johansson JE, et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010;102(13):950-958.
31. Baker SG, Kramer BS, Prorok PC. Statistical issues in randomized trials of cancer screening. BMC Med Res Methodol. 2002;2:11.
32. Nordström T, Aly M, Clements MS, Weibull CE, Adolfsson J, Grönberg H. Prostate specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol. 2013;63(3):419-425.
33. Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: the US Preventive Services Task Force and Prostate Cancer Screening. Med Care 2013;51(4):295-300.
34. Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE. 2008 US Preventive Service Task Force recommendations and prostate cancer screening rates. JAMA. 2012;307(16):1692-1694.
35. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013;346:f2023.